CALGARY, Alberta, Jan. 03, 2023 (GLOBE NEWSWIRE) -- FluroTech Ltd. (“ FluroTech ” or the “ Company ”) (TSXV: TEST) announces that it has entered into a Share Purchase Agreement (“ Agreement ”) to sell all of the shares of FluroTest Diagnostic Systems Ltd., a wholly-owned subsidiary of the Company, to an arm’s length individual (the “ Purchaser ”). The Purchaser has agreed to pay total cash consideration of $1.00 in lawful... Read More

CALGARY, Alberta, Nov. 29, 2022 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) (“ FluroTech ” or the “ Company ”) announces that it has decided to exit the pandemic and emerging disease industry immediately and halt any further expenditures on development of its Pandemic and Emerging Disease Defense Platform (“ PEDDP ”). Due to declining rates of COVID-19 and the establishment of testing protocols by various... Read More

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (the “ Company ” or “ FluroTech ”), announces that it has decided to pause any further expenditures on development of its Pandemic and Emerging Disease Defense Platform (“ PEDDP ”), initially targeting COVID-19, until it is able to obtain further financing. While management continues to believe that its COVID-19 testing technology will be viable and needed, the Company will require... Read More

FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a developer of diagnostics technology in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today provided a progress update on its efforts to bring its Pandemic Response Platform to market. About FluroTest Diagnostic Systems Ltd. FluroTest, a diagnostics... Read More

FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a developer of diagnostics technology in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today provided a progress update on its efforts to bring its Pandemic Response Platform to market. FluroTest has been developing its “Pandemic and Emerging Disease... Read More

FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ( "FluroTest" or The Company ), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today provided a progress update on efforts to bring its Pandemic Response Platform to market. Notable product developments include: Platform Development: FluroTest’s entire... Read More

FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ( "FluroTest" or The Company ), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announced it has filed its Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration (FDA). The Pre-EUA submission is the Company’s... Read More

FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ( "FluroTest" or The Company ), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to be recognized in Grand View Research’s June 2021 report: COVID-19 Saliva Screening Test Potential Market . According to the report, the global COVID-19 saliva... Read More

New CMO Preps Aggressive SARS-CoV-2 Global Testing and Education Agenda as Company Confirms Variant Detection Capabilities in High-Volume Testing System FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ( "FluroTest" or The Company ), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to... Read More

FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) (“ FluroTech ” or the “Company” ), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, and its wholly owned subsidiary FluroTest Diagnostic Systems Ltd. (“ FluroTest ”) are pleased to announce that further to FluroTech’s press releases dated February 3, 2021 and March 15, 2021, the Company, FluroTest, and 2330853... Read More

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (" FluroTech " or the " Company "), a leading developer of spectroscopy-based technology, is pleased to announce that further to its news releases dated April 12, 2021 and May 7, 2021, the Early Warrant Exercise Incentive Program (" EWEIP ") has been completed and that 5,213,612 Warrants (as defined and described below) were exercised at the price of $0.22 per Warrant for gross... Read More

FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostics Systems ( "FluroTest" or The Company ), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announces it has signed a strategic Memorandum of Understanding... Read More

Clinical Trial Progresses Across Six Clinical Site Locations Throughout the US FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostics Systems ( "FluroTest" or The Company ), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announces the next phase of its ongoing clinical trials with its trial partner Toolbox... Read More

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (" FluroTech " or the " Company "), a leading developer of spectroscopy-based technology, is pleased to announce that, further to its news release dated April 12, 2021, it has received TSX Venture Exchange (the " Exchange ") approval to extend the exercise the period of the Company’s Early Warrant Exercise Incentive Program (" EWEIP ") intended to encourage the early exercise of up... Read More

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and subsidiary FluroTest Diagnostics Systems ( "FluroTest" or The Company ), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce based on the data collected to date that the FluroTest platform will be capable... Read More

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and subsidiary FluroTest Diagnostics Systems ( "FluroTest" or The Company ), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announces it has signed a strategic Memorandum of Understanding ("MOU") with Total Testing... Read More

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (" FluroTech " or the " Company "), a leading developer of spectroscopy-based technology, is pleased to announce it has received conditional approval from the TSX Venture Exchange (the " Exchange ") to commence an Early Warrant Exercise Incentive Program (" EWEIP ") intended to encourage the early exercise of up to 18,550,000 Warrants (as defined and described below). In January of... Read More

Brings prior experience as US Representative to the World Health Organization Executive Board and expertise in health care delivery, health policy, international affairs and pandemic influenza planning to FluroTest team FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and subsidiary FluroTest Diagnostics Systems ( "FluroTest" or The Company ), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and... Read More

FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) is pleased to announce that it has granted incentive stock options the Board of Directors to purchase 225,000 common shares of FluroTech at a price of $0.45 per share for a term of two years in accordance with FluroTech’s stock option plan. The options will vest monthly over a 24-month period and have a life of 4 years. The issuance of the options is subject to final approval by the... Read More

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“ FluroTech ” or the “ Company ”), a leading developer of spectroscopy-based technology, and FluroTest Systems Ltd. (“ FluroTest ”), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce that, further to FluroTech’s press release dated February 3, 2021, FluroTest, the Company, and 2330853 Alberta Ltd., a... Read More

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”), a leading developer of spectroscopy-based technology, together with joint venture FluroTest, LLC (“FluroTest”), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce that an agreement with Toolbox Medical Innovations (“Toolbox”) has been signed this week to carry out clinical... Read More

FluroTech Ltd. ( TSXV: TEST ) ( OTCQB: FLURF ) (“FluroTech” or the “Company”), a leading developer of spectroscopy-based technology, together with joint venture partner FluroTest, LLC (“FluroTest”), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announced that visionary inventor and Hudson Robotics Founder and President Phil Farrelly has joined FluroTech’s... Read More

FluroTech Ltd. ( TSXV: TEST ) ( OTCQB: FLURF ) (“FluroTech” or the “Company”), a leading developer of spectroscopy-based technology, together with joint venture FluroTest, LLC (“FluroTest”), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announced that pre-production development of three functioning pandemic defense platform systems are now underway with... Read More

FluroTech Ltd. ( TSXV: TEST ) ( OTCQB: FLURF ) (“FluroTech” or the “Company”), a leading developer of spectroscopy-based technology, together with FluroTest, LLC (“FluroTest”), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announced that accomplished scientist and diagnostic test commercialization expert Dr. Timothy Holzer has joined FluroTech’s advisory board.... Read More

FluroTech Ltd. ( TSXV: TEST ) ( OTCQB: FLURF ) (“FluroTech” or the “Company”), a leading developer of spectroscopy-based technology, together with FluroTest, LLC (“FluroTest”), a first-mover in surge-scale rapid antigen testing for the detection of COVID-19 and other pathogens, today announced that Brian Shield has joined FluroTech’s advisory board. Mr. Shield will help guide the Company’s business and innovation strategy,... Read More

FluroTech Ltd. ( TSXV: TEST ) ( OTCQB: FLURF ) (“FluroTech” or the “Company”), a leading developer of spectroscopy-based technology, together with FluroTest, LLC (“FluroTest”), a first-mover in surge-scale rapid antigen testing for the detection of COVID-19 and other pathogens, today announced that it is actively working and achieving major milestones as the Company prepares its application for emergency use authorization... Read More

FluroTech Ltd. ( TSXV: TEST ) ( OTCQB: FLURF ) (“FluroTech” or the “Company”), is pleased to announce that is has engaged Venture Liquidity Providers Inc. (“VLP”), subject to regulatory approval, to provide market-making services for the purpose of maintaining an orderly trading market and improving the liquidity of the Company’s shares. The market-making service will be undertaken by VLP through a registered broker, W.D.... Read More

FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”), is pleased to announce that, FluroTest Ltd. (“FluroTest”) has retained San Diego-based nanoComposix, a leading life sciences nanotechnology company that specializes in R&D and manufacturing of lateral flow rapid tests, to immediately begin lab performance studies for FluroTest’s rapid antigen testing pandemic defense platform. This move builds upon... Read More